• Stealth BioTherapeutics Corp (NASDAQ: MITO) has presented new data from a study evaluating SBT-272 in a murine model of Parkinson's disease (PD).

• SBT-272 is a mitochondria-targeted product candidate, which is known to cross the blood-brain barrier.

• The data were presented at the International Parkinson and Movement Disorder Society Virtual Congress 2021.

• Systemic daily administration of SBT-272 at two doses significantly protected against the loss of dopaminergic neurons and the aggregation of pathological alpha-synuclein.

• In addition, the higher dose of SBT-272 significantly reduced two different markers of neuroinflammation. Overall, the data demonstrate that SBT-272 has a neuroprotective effect in this model of PD.

• In this study, systemic SBT-272 treatment protected brain mitochondria against damage caused by an ischemic stroke.

• The Company plans to advance SBT-272 in dose-ranging Phase 1 studies early next year in addition to initiating chronic toxicology studies to support Phase 2 initiation.

• Price Action: MITO stock is down 1.37% at $1.44 during the market session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• RedHill Settles Movantik Patent Litigation With Aurobindo

• Incyte, Knight Therapeutics Ink Distribution Pact For Two Cancer Drugs In Latin America

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.